Short-term Effect of Hypergastrinemia Following Esomeprazole Treatment On Well-Controlled Type 2 Diabetes Mellitus: A Prospective Study.
CONCLUSION: Our study demonstrates that esomeprazole has no extra benefit for the controlled diabetic patient in three months. However, in only metformin-treated subgroup, esomeprazole may prevent the rise in HbA1c level.
PMID: 31995024 [PubMed - as supplied by publisher]
Source: Endocrine, Metabolic and Immune Disorders Drug Targets - Category: Drugs & Pharmacology Tags: Endocr Metab Immune Disord Drug Targets Source Type: research
More News: Diabetes | Diabetes Mellitus | Diabetes Type 2 | Drugs & Pharmacology | Endocrinology | Esomeprazole | Fortamet | Gastroenterology | Metformin | Nexium | Proton Pump Inhibitors PPIs | Statistics | Study